AI platform demonstrates promising results in treating patient with rare cancer
Researchers from NUS Medicine's WisDM used CURATE.AI to treat a patient with Waldenström macroglobulinemia, achieving improved red blood cell levels and cost savings. The AI platform, which adjusts treatment based on individual responses, demonstrates potential for personalized rare disease treatments despite small patient populations.
Highlighted Terms
Related News
NUS Medicine's WisDM researchers used AI platform CURATE.AI to treat a patient with Waldenström macroglobulinemia, a rare blood disorder. The platform, designed for rare diseases, leverages small data sets to personalize treatments, dynamically adjusting dosages based on patient responses. The patient experienced significant improvements, fewer hospital admissions, and lower medication costs, with initial trial results published in 'NPJ Digital Medicine'.
Researchers from NUS Medicine's WisDM used CURATE.AI to treat a patient with Waldenström macroglobulinemia, achieving improved red blood cell levels and cost savings. The AI platform, which adjusts treatment based on individual responses, demonstrates potential for personalized rare disease treatments despite small patient populations.